UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in GRAIL, Inc. $GRAL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 16.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 66,077 shares of the company’s stock after buying an additional 9,094 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in GRAIL were worth $4,511,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. BlackRock Inc. raised its position in shares of GRAIL by 20.5% during the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after purchasing an additional 608,539 shares during the period. Farallon Capital Management LLC grew its position in shares of GRAIL by 73.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares in the last quarter. Primecap Management Co. CA bought a new stake in shares of GRAIL in the second quarter worth about $148,836,000. Baker BROS. Advisors LP increased its holdings in shares of GRAIL by 27.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after purchasing an additional 455,208 shares during the last quarter. Finally, State Street Corp lifted its position in shares of GRAIL by 38.8% in the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after buying an additional 510,546 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Aaron Freidin sold 7,900 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00. Following the transaction, the chief financial officer directly owned 253,083 shares in the company, valued at approximately $21,514,585.83. This represents a 3.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua J. Ofman sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $85.02, for a total transaction of $425,100.00. Following the completion of the sale, the chief executive officer directly owned 397,271 shares of the company’s stock, valued at approximately $33,775,980.42. The trade was a 1.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

GRAL has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Wall Street Zen downgraded GRAIL from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Wolfe Research initiated coverage on GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, UBS Group began coverage on shares of GRAIL in a report on Wednesday. They issued a “buy” rating and a $105.00 target price for the company. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $71.11.

GRAIL Price Performance

Shares of NASDAQ GRAL opened at $77.48 on Thursday. GRAIL, Inc. has a 1-year low of $35.39 and a 1-year high of $118.84. The business’s 50 day moving average is $73.18 and its two-hundred day moving average is $62.26. The stock has a market capitalization of $3.46 billion, a P/E ratio of -7.95 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, equities research analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.